This clinical trial is focused on studying a kidney disease called Immunoglobulin A Nephropathy (IgAN). IgAN is a condition where a protein called IgA builds up in the kidneys, causing inflammation and affecting their ability to filter waste from the blood. The trial will evaluate a treatment called Sibeprenlimab, which is a type of medication known as a monoclonal antibody. Monoclonal antibodies are proteins made in a lab that can bind to specific substances in the body. Sibeprenlimab is administered as a solution for injection under the skin, a method known as subcutaneous use. The study will also involve a placebo, which is a substance with no active medication, to compare the effects of Sibeprenlimab.

The purpose of the study is to assess the effectiveness and safety of Sibeprenlimab in treating IgAN. Participants in the trial will receive either Sibeprenlimab or a placebo, in addition to their standard care, for a period of nine months. The trial will monitor changes in the levels of protein in the urine, which is a key indicator of kidney function. The study will also track the overall health and kidney function of participants over a longer period to gather more information about the treatment’s impact.

Throughout the trial, participants will undergo regular check-ups and tests to ensure their safety and to collect data on how well the treatment is working. The trial aims to provide valuable insights into whether Sibeprenlimab can be an effective treatment option for people with IgAN, potentially improving their kidney health and quality of life.